Document Detail


Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children.
MedLine Citation:
PMID:  7838548     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine the biologic behavior, risk factors for recurrence, and influence of multimodality therapy on outcome for children and adults with rhabdomyosarcoma of the nose and paranasal sinuses. DESIGN: Retrospective review of medical records. PATIENTS: During a 36-year period 37 patients (median age, 23.0 years) with histologically confirmed rhabdomyosarcoma of the nose and paranasal sinuses were treated for cure. Median follow-up was 28 months (range, 1 to 260 months). Histologic subtypes included embryonal, 16; alveolar, 15; mixed, 1; and unclassified, 5. Cervical metastases were present in 38%. Patients were treated with surgery, 4; radiotherapy, 3; chemotherapy, 3; surgery and radiotherapy, 1; surgery and chemotherapy, 1; chemotherapy and radiotherapy, 24; and chemotherapy, radiotherapy, and surgery, 1. RESULTS: The overall 5-year survival was 44%. For patients treated with chemotherapy and radiotherapy or chemotherapy, radiotherapy, and surgery, the 5-year survival was 60%, compared with 19% for patients treated with the other forms of therapy. Factors associated with poorer survival were adult onset of disease, alveolar histology, and treatment with systemic chemotherapy for less than 1 year. Patients receiving chemotherapy for greater than 1 year had a 5-year survival of 82%, compared with 71% for those with less than 1 year of treatment. Improved survival was associated with a lower incidence of distant metastasis. CONCLUSIONS: A combination of chemotherapy and radiotherapy may provide the best means of obtaining local-regional control for rhabdomyosarcoma arising in the nose and paranasal sinuses. The risk of regional disease is high, requiring comprehensive radiotherapy to the neck in addition to the primary site. Surgical resection should be reserved for patients with residual disease after chemotherapy and radiotherapy. Administration of chemotherapy for more than 1 year is associated with improved survival because of a decreased incidence of metastatic disease.
Authors:
T A Callender; R S Weber; N Janjan; R Benjamin; M Zaher; P Wolf; A el-Naggar
Related Documents :
18544988 - Radiotherapy in biochemical recurrences after surgery for prostate cancer.
14605058 - High relapse-free survival after preoperative and intraoperative radiotherapy and resec...
9385848 - Swallowing performance after radiotherapy for squamous cell carcinoma oesophagus.
12714878 - Palliative thoracic radiotherapy for non-small-cell lung cancer: a systematic review.
24249458 - Expression of apoptosis regulating proteins identifies stage ii and iii colon cancer pa...
23333018 - Gtv differentially impacts locoregional control of non-small cell lung cancer (nsclc) a...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery     Volume:  112     ISSN:  0194-5998     ISO Abbreviation:  Otolaryngol Head Neck Surg     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-03-02     Completed Date:  1995-03-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8508176     Medline TA:  Otolaryngol Head Neck Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  252-7     Citation Subset:  IM    
Affiliation:
Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Aged
Child
Child, Preschool
Cohort Studies
Combined Modality Therapy
Female
Follow-Up Studies
Head and Neck Neoplasms / secondary
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Nose Neoplasms / pathology,  therapy*
Paranasal Sinus Neoplasms / pathology,  therapy*
Retrospective Studies
Rhabdomyosarcoma / pathology,  secondary,  therapy*
Rhabdomyosarcoma, Alveolar / pathology,  secondary,  therapy
Rhabdomyosarcoma, Embryonal / pathology,  secondary,  therapy
Risk Factors
Survival Rate
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Radiation exposure in paranasal sinus imaging.
Next Document:  Analysis of the pharyngoesophageal pressure profile in amyotrophic lateral sclerosis.